Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
Closing of equity offering of 2,776,000 series H shares by private placement, offered within the authorised capital, at an issue price of PLN 18 per share Series H shares were subscribed for by 35 investors, new
Read more
Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.
The agreement with Simbec-Orion includes organizing and fully executing a proof-of-concept Phase II clinical trial in patients with pulmonary sarcoidosis. The Phase II proof-of-concept study of OATD-01 will be conducted as multi-center and international clinical trial
Read more
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compounds First patient dosed in Phase I trial with OATD-02, a novel, first in class dual arginase inhibitor for the treatment of cancer Lead
Read more
Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy
Dr Zbigniew Zasłona, PhD promoted to Chief Scientific Officer – Dr Zasłona remains a member of Molecure’s Management Board Dr Adam Gołębiowski transitioning from management board position to take on role of Senior Research Fellow
Read more
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Warsaw, Poland – 5 December 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein
Read more
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results Proprietary pipeline progressing in-line with our strategic objectives for 2022-2025 Lead proprietary candidate, OATD-01 a novel chitinase inhibitor in sarcoidosis expected to advance into a Phase II
Read more
Marta Dudek
Marta Dudek, MD, PhD, received her PhD degree in biochemistry from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, in collaboration with the University of Warsaw in 2012. She has worked with oncological patients
Read more
Paul Van der Horst, PhD
Dr van der Horst has a strong track record of biotech business development having acted as lead negotiator in over 20 licensing and M&A transactions and raised over $1.3 billion through capital market transactions during his
Read more
Bruce Conway
Senior advisor, Biology & Pharmacology. Bruce is a scientific leader with over 18 years of experience in both large and small pharmaceutical organizations. While at Johnson & Johnson, Bruce served as the project leader for numerous
Read more